CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:
- To understand and address, through clinical and translational research, the disease burden associated with advanced prostate cancer in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to advanced prostate cancer.
- To update, review, and discuss recent results of clinical studies conducted by the Canadian Cancer Trials Group and/or by national international collaborators.
- To provide mentoring opportunities for investigators new to clinical trial research.
- To understand and apply new clinical trial methodologies in the field of clinical research related to advanced prostate cancer.

8:00 am Welcome K. Chi

CCTG Approved TRIALS

8:05 am PR.18/TOPARP: Phase II double-blind placebo controlled trial of olaparib 400mg BID vs placebo in unselected patients with advanced castration resistant prostate cancer who have not received taxane-based chemotherapy. K. Chi

8:10 am IND.232: A Phase II Study of Durvalumab (Medi4736) with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer S. Hotte

TRIAL PROPOSAL UPDATE

8:15 am PRIME: Prevention and intervention for metabolic syndrome. N. Usmani / B. Eigl

continued on next page …
New TRIAL PROPOSALS

8:25 am  CRPC Umbrella Trials  K. Chi

8:35 am  SWOG Randomized phase III trial of best standard therapy or best standard therapy plus surgical treatment of the primary tumor in metastatic prostate cancer,  K. Chi

New TRIAL CONCEPTS

8:45 am  ECOG-ACRIN CHAARTED2: Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel  K. Chi

ECOG-ACRIN ERADICATE: Early Intervention after Radical Prostatectomy with Enzalutamide or Docetaxel versus Androgen Deprivation Therapy in Men at Highest Risk of Metastasis by Genomic Stratification.

ALLIANCE: Phase III Androgen annihilation in BCR

9:00 am  Meeting adjourned